Press Releases 01.05.2016
Editas Medicine Expands Leadership Team with Key Organizational Appointments
Cambridge, Mass., January 5, 2015 – Editas Medicine, a leading genome editing company, today announced the appointment of Timothy D. Hunt as senior vice president of corporate affairs and Haiyan Jiang, Ph.D., as vice president of preclinical science.
“The addition of Tim and Haiyan expands and strengthens our leadership team,” said Katrine Bosley, CEO, Editas Medicine. “Both bring significant experience in their respective fields, and they share our commitment to realizing the potential of our genome editing platform and developing medicines for patients with many different genetically defined diseases.”
Prior to joining Editas Medicine, Mr. Hunt served as senior vice president of public affairs for Cubist Pharmaceuticals, before the company was acquired by Merck in 2015. Before joining Cubist, Mr. Hunt spent several years at Biogen Idec, where he most recently served as vice president of public affairs, overseeing global communications. Previously, Mr. Hunt also served in government affairs for GlaxoSmithKline, as well as for former Massachusetts governor, William F. Weld. Mr. Hunt received his J.D. from the Columbus School of Law at the Catholic University of America and his B.A. from Boston College.
Dr. Jiang joins Editas Medicine from Biogen, where she most recently served as senior director of cell and gene therapy. Prior to joining Biogen, Dr. Jiang served in multiple roles at Bayer HealthCare Pharmaceuticals, including deputy director of pharmacology for hematology and applied research. Dr. Jiang began her career as a scientist at Avigen. She received her B.S. from Fudan University in Shanghai, China and her Ph.D. in oncology from the University of Wisconsin–Madison. She was a postdoctoral research associate in the lab of Dr. Frank McCormick, FRS, at the University of California, San Francisco.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients. For more information, visit www.editasmedicine.com.